Key result
ICD deactivation at the end of life remains a major clinical challenge, with the incidence of multiple futile shocks in the final hours of life estimated at 8-16%.
ICD deactivation at the end of life is a critical but often delayed discussion, highlighting the need for improved end-of-life care planning in patients with ICDs.
Answers are grounded in this paper and cite their sources.
Proactive end-of-life ICD planning is warranted to curb futile shocks; leaves open standardized deactivation protocols.
It is inevitable that all patients with implantable cardioverter-defibrillators (ICDs) will die during extended follow-up. End-of-life care planning may become appropriate as a patient's condition deteriorates. There is concern about multiple futile shocks in the final hours of life, although the incidence of this problem has been estimated at only 8-16%. Despite broad consensus that ICD deactivation should be discussed as part of end-of-life care planning, the effect of ICD deactivation, in particular whether life expectancy is altered, is uncertain. Many clinicians are reluctant to discuss ICD deactivation. Many patients have misconceptions regarding ICD function and value longevity above quality of life. As such, ICD deactivation is often discussed late or not at all. The management of ICDs in patients approaching death is likely to become a major problem in the coming years. This article will discuss directions in which clinical practice might develop and areas for future research.
No takes yet. Share an insight, caveat, or question.
Pettit et al. (2013) conducted a review in Implantable cardioverter-defibrillators at end of life. ICD deactivation was evaluated. ICD deactivation at the end of life remains a major clinical challenge, with the incidence of multiple futile shocks in the final hours of life estimated at 8-16%.
Synapse has enriched 10 related papers. Consider them for comparative context: